US5352456A
(en)
*
|
1991-10-10 |
1994-10-04 |
Cygnus Therapeutic Systems |
Device for administering drug transdermally which provides an initial pulse of drug
|
FR2735027B1
(fr)
*
|
1995-06-07 |
1998-01-09 |
Alza Corp |
Compositions de renforcateurs de permeation d'agents a travers la peau, comprenant de l'acetate de lauryle et un monoglyceride
|
US5785991A
(en)
*
|
1995-06-07 |
1998-07-28 |
Alza Corporation |
Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
|
US20040265353A1
(en)
*
|
1995-07-28 |
2004-12-30 |
Zars, Inc. |
Systems and methods for treating panic attacks
|
US20020114827A1
(en)
*
|
1995-07-28 |
2002-08-22 |
Jie Zhang |
Methods and apparatus for improved administration of analgesics
|
DE19546024C2
(de)
*
|
1995-12-09 |
1998-09-10 |
Lohmann Therapie Syst Lts |
Transdermale pharmazeutische Zubereitung und deren Herstellung
|
US5686096A
(en)
*
|
1995-12-22 |
1997-11-11 |
Becton Dickinson And Company |
Medical device for the protection of a catheter penetration site
|
US5730721A
(en)
|
1996-01-25 |
1998-03-24 |
Vesture Corporation |
Medical applicator and method
|
US5837289A
(en)
*
|
1996-07-23 |
1998-11-17 |
Grasela; John C. |
Transdermal delivery of medications using a combination of penetration enhancers
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
AU758193B2
(en)
*
|
1996-09-17 |
2003-03-20 |
U.D. Testing, Inc. |
Therepeutic agent with quantitative consumption marker
|
AU736645B2
(en)
*
|
1996-09-17 |
2001-08-02 |
U.D. Testing, Inc. |
Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption
|
US6660295B2
(en)
|
1997-09-30 |
2003-12-09 |
Alza Corporation |
Transdermal drug delivery device package with improved drug stability
|
AU1728099A
(en)
|
1997-12-22 |
1999-07-12 |
Alza Corporation |
Monoglyceride and ethyl palmitate permeation enhancer compositions
|
US5900249A
(en)
*
|
1998-02-09 |
1999-05-04 |
Smith; David J. |
Multicomponent pain relief topical medication
|
US6136801A
(en)
*
|
1998-12-24 |
2000-10-24 |
U. D. Testing, Inc. |
Therapeutic agent with quantitative consumption marker
|
KR20010036685A
(ko)
|
1999-10-11 |
2001-05-07 |
김윤 |
펜타닐을 함유하는 매트릭스형 경피투여제
|
WO2001064149A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Jie Zhang |
Improved transdermal drug patch
|
US7713546B1
(en)
|
2001-04-03 |
2010-05-11 |
Soft Gel Technologies, Inc. |
Corosolic acid formulation and its application for weight-loss management and blood sugar balance
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
GB0026137D0
(en)
*
|
2000-10-25 |
2000-12-13 |
Euro Celtique Sa |
Transdermal dosage form
|
DE10102817B4
(de)
*
|
2001-01-23 |
2006-01-12 |
Lts Lohmann Therapie-Systeme Ag |
Vorrichtung und Verfahren zur Hitzepulsgestützten transdermalen Applikation von Wirkstoffen
|
US20030118653A1
(en)
*
|
2001-07-06 |
2003-06-26 |
Lavipharm Laboratories Inc. |
Quick dissolving oral mucosal drug delivery device with moisture barrier coating
|
AU2002329763B2
(en)
*
|
2001-08-17 |
2007-11-08 |
Lavipharm Laboratories Inc. |
Composition and transdermal drug delivery device
|
KR100844312B1
(ko)
*
|
2001-09-06 |
2008-07-07 |
노사케미컬(주) |
펜타닐 경피 투여 제제
|
DK1469723T3
(da)
*
|
2002-01-31 |
2007-03-05 |
Disease Control Textiles Sa |
Lamineret insekticiddoseringsorgan
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
AU2003252075A1
(en)
*
|
2002-07-16 |
2004-02-02 |
University Of South Florida |
Human immunosuppressive protein
|
EP2316459B1
(de)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
|
CN100336569C
(zh)
*
|
2002-10-20 |
2007-09-12 |
浙江大学 |
经皮给药电穿孔系统
|
US7241456B2
(en)
*
|
2002-10-25 |
2007-07-10 |
Australian Importers Ltd. |
Formulations for topical delivery of bioactive substances and methods for their use
|
WO2004045601A1
(en)
|
2002-11-18 |
2004-06-03 |
Yaupon Therapeutics, Inc. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
US20070031463A1
(en)
*
|
2003-02-26 |
2007-02-08 |
Spiros Fotinos |
Methods and devices for releasing volatile substances
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
ATE506953T1
(de)
|
2003-08-07 |
2011-05-15 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
DE602004024228D1
(de)
|
2003-10-27 |
2009-12-31 |
Univ Basel |
Transdermales arzneimittelabgabesystem
|
US7105263B2
(en)
*
|
2003-12-30 |
2006-09-12 |
Samsung Electronics Company |
Dry toner comprising encapsulated pigment, methods and uses
|
US20050186269A1
(en)
*
|
2004-02-25 |
2005-08-25 |
Udell Ronald G. |
Stabilized feverfew formulations
|
US20060008432A1
(en)
*
|
2004-07-07 |
2006-01-12 |
Sebastiano Scarampi |
Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
|
US20060051435A1
(en)
*
|
2004-08-19 |
2006-03-09 |
Udell Ronald G |
Nutritional supplement for body fat reduction
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
EP1802258A4
(de)
|
2004-09-13 |
2015-09-23 |
Chrono Therapeutics Inc |
Biosynchrone transdermale arzneiabgabe
|
US8372040B2
(en)
*
|
2005-05-24 |
2013-02-12 |
Chrono Therapeutics, Inc. |
Portable drug delivery device including a detachable and replaceable administration or dosing element
|
CA2609351C
(en)
|
2005-05-24 |
2015-01-06 |
Chrono Therapeutics Inc. |
Portable drug delivery device
|
US20070104805A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Udell Ronald G |
Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
|
AT502717A1
(de)
*
|
2005-11-09 |
2007-05-15 |
Omnica Gmbh |
Pharmazeutische verwendung einer verbindung
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
WO2007092350A1
(en)
*
|
2006-02-02 |
2007-08-16 |
H.B. Fuller Licensing & Financing, Inc. |
Wound care articles, drug delivery systems and methods of using the same
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
EP2007877B1
(de)
|
2006-02-28 |
2013-04-17 |
The Trustees of Columbia University in the City of New York |
Verfahren für kompakte aggregation von hautzellen
|
AT503521A1
(de)
*
|
2006-05-05 |
2007-11-15 |
Omnica Gmbh |
Verwendung eines extraktes von kiwi-frucht
|
EP2037999B1
(de)
|
2006-07-07 |
2016-12-28 |
Proteus Digital Health, Inc. |
Intelligentes parenterales verabreichungssystem
|
JP2008044926A
(ja)
*
|
2006-08-14 |
2008-02-28 |
Trustees Of Columbia Univ In The City Of New York |
Wnt信号伝達に関係した分泌タンパク質
|
DK2078026T3
(da)
|
2006-11-21 |
2012-04-30 |
Rigel Pharmaceuticals Inc |
Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
|
US7820207B2
(en)
*
|
2007-03-15 |
2010-10-26 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
US8623429B2
(en)
|
2007-03-15 |
2014-01-07 |
Omnica Gmbh |
Stabilized anthocyanin compositions
|
US20080293644A1
(en)
*
|
2007-04-27 |
2008-11-27 |
Thomas Eidenberger |
Guava extract
|
WO2009027850A2
(en)
*
|
2007-06-06 |
2009-03-05 |
Multi-Tech Specialty Chemicals Co., Ltd. |
Process for the preparation of xanthophyll crystals
|
WO2009002935A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Sciele Pharma, Inc. |
Transdermal delivery system comprising glycopyrrolate to treat sialorrhea
|
JP5243548B2
(ja)
|
2007-10-25 |
2013-07-24 |
プロテウス デジタル ヘルス, インコーポレイテッド |
情報システムのための流体伝達ポート
|
WO2009105140A2
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
WO2009089380A2
(en)
*
|
2008-01-08 |
2009-07-16 |
The Trustees Of Columbia University In The City Of New York |
Methods for p2ry5 mediated regulation of hair growth and mutants thereof
|
US20090270398A1
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Pyridazine Derivatives
|
WO2009131951A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
WO2009131957A2
(en)
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising oxadiazole derivatives
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
EP2367812B1
(de)
*
|
2008-08-22 |
2015-09-16 |
Sanofi |
[4-(5-aminomethyl-2-fluorphenyl)piperidin-1-yl]-[7-fluor-1-(2-methoxyethyl)-4-trifluormethoxy-1h-indol-3-yl]methanon als inhibitor von mastzellentryptase
|
US20110237528A1
(en)
*
|
2008-09-19 |
2011-09-29 |
Institute For Oneworld Health |
Compositions and methods comprising imidazole and triazole derivatives
|
TW201034675A
(en)
|
2008-12-18 |
2010-10-01 |
Sanofi Aventis |
Method for treating macular degeneration
|
JP5815411B2
(ja)
|
2008-12-30 |
2015-11-17 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ピリミジンジアミンキナーゼ阻害剤
|
ES2473584T3
(es)
|
2009-01-23 |
2014-07-07 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
CN104523661A
(zh)
|
2009-02-06 |
2015-04-22 |
南加利福尼亚大学 |
含有单萜的治疗组合物
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
EP2641906B1
(de)
|
2009-07-08 |
2015-04-22 |
Dermira (Canada), Inc. |
Tofa-Analoga zur Behandlung von Hauterkrankungen oder -Störungen
|
US20110034415A1
(en)
*
|
2009-07-20 |
2011-02-10 |
Thomas Eidenberger |
Walnut extracts for nutraceutical applications
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
US20110144200A1
(en)
|
2009-12-14 |
2011-06-16 |
Thomas Eidenberger |
Combination of carotenoids and epi-lutein
|
RU2012131280A
(ru)
|
2009-12-23 |
2014-02-10 |
Санофи |
[4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
|
EP2516418B1
(de)
|
2009-12-23 |
2014-05-14 |
Sanofi |
Prodrugs von [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanonen und synthese davon
|
SG182824A1
(en)
|
2010-02-01 |
2012-09-27 |
Proteus Biomedical Inc |
Two-wrist data gathering system
|
CA2788336C
(en)
|
2010-02-01 |
2018-05-01 |
Proteus Digital Health, Inc. |
Data gathering system
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
US20110288093A1
(en)
|
2010-04-20 |
2011-11-24 |
Institute For Oneworld Health |
Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
|
EP2560643A1
(de)
|
2010-04-20 |
2013-02-27 |
Institute for OneWorld Health |
Verbindungen, zusammensetzungen und verfahren mit 1,3,4-oxadiazol-derivaten
|
KR101379370B1
(ko)
|
2010-04-24 |
2014-03-28 |
비아멧 파마슈티컬즈, 인코포레이티드 |
금속효소 억제제 화합물
|
US20120208855A1
(en)
|
2010-07-12 |
2012-08-16 |
Sanofi |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
MX347331B
(es)
|
2010-07-28 |
2017-04-21 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la via jak.
|
CA2816088A1
(en)
|
2010-10-28 |
2012-05-03 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
PT2635299T
(pt)
|
2010-11-02 |
2019-10-14 |
Univ Columbia |
Métodos de tratamento de distúrbios de perda de cabelo
|
KR20180039185A
(ko)
|
2010-11-13 |
2018-04-17 |
이노크린 파마슈티컬즈, 인크. |
금속효소 억제제 화합물
|
CN103328452A
(zh)
|
2010-12-13 |
2013-09-25 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
EP2678297A2
(de)
|
2011-02-25 |
2014-01-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chrysophaentin-analoga als hemmer des ftsz-proteins
|
CN103501821A
(zh)
|
2011-03-08 |
2014-01-08 |
艾克塞斯制药公司 |
用于递送活性剂穿过生物膜的靶向纳米载体系统
|
WO2012177603A2
(en)
|
2011-06-19 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
WO2012177635A1
(en)
|
2011-06-19 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
CA2838916C
(en)
|
2011-06-23 |
2020-08-11 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
US20130017259A1
(en)
|
2011-07-06 |
2013-01-17 |
The Parkinson's Institute |
Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
|
WO2013019169A1
(en)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Phosphate prodrugs
|
AU2012301617A1
(en)
|
2011-09-02 |
2014-04-17 |
Salk Institute For Biological Studies |
CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity
|
US9309273B2
(en)
|
2011-12-11 |
2016-04-12 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
ES2774267T3
(es)
|
2012-01-20 |
2020-07-20 |
Mycovia Pharmaceuticals Inc |
Compuestos inhibidores de metaloenzimas
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス, インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
PL2830662T3
(pl)
|
2012-03-29 |
2019-02-28 |
The Trustees Of Columbia University In The City Of New York |
Sposoby leczenia zaburzeń utraty włosów
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
US10105487B2
(en)
|
2013-01-24 |
2018-10-23 |
Chrono Therapeutics Inc. |
Optimized bio-synchronous bioactive agent delivery system
|
US20140213555A1
(en)
|
2013-01-25 |
2014-07-31 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating autoimmune diseases
|
US9006462B2
(en)
|
2013-02-28 |
2015-04-14 |
Dermira, Inc. |
Glycopyrrolate salts
|
ES2699257T3
(es)
|
2013-02-28 |
2019-02-08 |
Dermira Inc |
Sales de glicopirrolato
|
JP2016515508A
(ja)
|
2013-03-15 |
2016-05-30 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
融合タンパク質及びその方法
|
KR101831290B1
(ko)
*
|
2013-10-07 |
2018-02-22 |
테이코쿠 팔마 유에스에이, 인코포레이티드 |
덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
|
ES2847936T3
(es)
|
2013-10-07 |
2021-08-04 |
Teikoku Pharma Usa Inc |
Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
|
KR101827980B1
(ko)
|
2013-10-07 |
2018-02-13 |
테이코쿠 팔마 유에스에이, 인코포레이티드 |
덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
|
JP6469587B2
(ja)
|
2013-12-18 |
2019-02-13 |
丸石製薬株式会社 |
含水型貼付剤
|
EP3119415A4
(de)
|
2014-03-07 |
2017-11-29 |
The Arizona Board of Regents on behalf of the University of Arizona |
Gegen natriumkanäle gerichtete nicht-narkotische crmp2-peptide für chronische schmerzen
|
CA2942231A1
(en)
|
2014-03-19 |
2015-09-24 |
Viamet Pharmaceuticals, Inc. |
Antifungal compound process
|
EP3237452A4
(de)
|
2014-12-23 |
2018-12-05 |
The Trustees of Columbia University in the City of New York |
Fusionsproteine und verfahren dafür
|
US10213586B2
(en)
|
2015-01-28 |
2019-02-26 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
AU2016228779A1
(en)
|
2015-03-12 |
2017-09-07 |
Chrono Therapeutics Inc. |
Craving input and support system
|
EP3271347B1
(de)
|
2015-03-19 |
2022-06-22 |
Mycovia Pharmaceuticals, Inc. |
Fungizide verbindungen und verfahren zur herstellung
|
JP6994454B2
(ja)
|
2015-08-04 |
2022-01-14 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
|
EA037521B1
(ru)
|
2015-09-18 |
2021-04-07 |
ВиПиЭс-3, ИНК. |
Противогрибковые соединения и способы их получения
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
MX2018008105A
(es)
|
2015-12-30 |
2018-11-12 |
Vps 3 Inc |
Compuestos inhibidores de metaloenzima.
|
ES2957234T3
(es)
*
|
2016-03-24 |
2024-01-15 |
Medrx Co Ltd |
Preparación de parche con características de prevención del uso incorrecto de sustancias
|
US20170273974A1
(en)
|
2016-03-24 |
2017-09-28 |
Medrx Co., Ltd |
Patch preparations with misuse prevention features
|
WO2018005356A1
(en)
|
2016-06-27 |
2018-01-04 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and method for making and using the compounds
|
WO2018002888A1
(en)
|
2016-06-29 |
2018-01-04 |
Halo Life Science, Llc |
Methods of making low odor choline salts of an organic compound
|
CN110099899B
(zh)
|
2016-10-26 |
2024-01-02 |
里格尔药品股份有限公司 |
用作irak抑制剂的噁唑衍生物及其制备方法
|
WO2018081294A1
(en)
|
2016-10-26 |
2018-05-03 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
AU2017387033B2
(en)
|
2016-12-29 |
2024-02-01 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
EP3562306A4
(de)
|
2016-12-29 |
2020-06-24 |
Selenity Therapeutics (Bermuda), Ltd. |
Metalloenzym-inhibitor-verbindungen
|
JP6868698B2
(ja)
|
2016-12-31 |
2021-05-12 |
バイオエクセル セラピューティクス,インコーポレイテッド |
激越の治療のための舌下デクスメデトミジンの使用
|
WO2018129304A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
JP7167069B2
(ja)
|
2017-06-29 |
2022-11-08 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
キナーゼ阻害剤ならびに作製および使用のための方法
|
DK3788044T3
(da)
|
2018-05-03 |
2023-10-02 |
Rigel Pharmaceuticals Inc |
RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
|
FI3788045T3
(fi)
|
2018-05-03 |
2023-06-28 |
Rigel Pharmaceuticals Inc |
RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä
|
AU2019279884A1
(en)
|
2018-05-29 |
2020-12-10 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|
MX2020014000A
(es)
|
2018-06-27 |
2021-06-15 |
Bioxcel Therapeutics Inc |
Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
TWI772807B
(zh)
|
2019-05-27 |
2022-08-01 |
日商救急藥品工業股份有限公司 |
外用製劑
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
BR112022000992A2
(pt)
|
2019-07-19 |
2022-06-14 |
Arx Llc |
Regimes de tratamento de dexmedetomidina não sedantes
|
MX2022001596A
(es)
|
2019-08-08 |
2022-03-11 |
Rigel Pharmaceuticals Inc |
Compuestos y metodos para tratar sindrome de liberacion de citocinas.
|
EP4013420B1
(de)
|
2019-08-14 |
2023-11-01 |
Rigel Pharmaceuticals, Inc. |
Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms
|
JP2022545542A
(ja)
|
2019-08-30 |
2022-10-27 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ピラゾール化合物、その製剤並びに化合物及び/又は製剤を使用する方法
|
MX2022002717A
(es)
|
2019-09-06 |
2022-08-10 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
|
KR20220042431A
(ko)
|
2019-09-06 |
2022-04-05 |
리겔 파마슈티칼스, 인크. |
헤테로시클릭 rip1 키나제 억제제
|
CN115298184A
(zh)
|
2019-11-07 |
2022-11-04 |
里格尔药品股份有限公司 |
杂环rip1抑制化合物
|
US20220288047A1
(en)
|
2021-03-03 |
2022-09-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
TW202346291A
(zh)
|
2022-03-23 |
2023-12-01 |
美商雷傑製藥公司 |
作為irak抑制劑的嘧啶—2—基—吡唑化合物
|
US20230312568A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|